These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 37195412)
21. Causes of death in mucopolysaccharidoses. Rintz E; Banacki M; Ziemian M; Kobus B; Wegrzyn G Mol Genet Metab; 2024 Jul; 142(3):108507. PubMed ID: 38815294 [TBL] [Abstract][Full Text] [Related]
22. Adeno-associated viral gene therapy for mucopolysaccharidoses exhibiting neurodegeneration. Lau AA; Hemsley KM J Mol Med (Berl); 2017 Oct; 95(10):1043-1052. PubMed ID: 28660346 [TBL] [Abstract][Full Text] [Related]
23. Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations - Neurological signs and symptoms. Shapiro EG; Jones SA; Escolar ML Mol Genet Metab; 2017 Dec; 122S():1-7. PubMed ID: 29074036 [TBL] [Abstract][Full Text] [Related]
24. Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: a potential therapeutic approach for Sanfilippo disease. Dziedzic D; Wegrzyn G; Jakóbkiewicz-Banecka J Eur J Hum Genet; 2010 Feb; 18(2):200-5. PubMed ID: 19690584 [TBL] [Abstract][Full Text] [Related]
25. Cellular Organelle-Related Transcriptomic Profile Abnormalities in Neuronopathic Types of Mucopolysaccharidosis: A Comparison with Other Neurodegenerative Diseases. Wiśniewska K; Gaffke L; Żabińska M; Węgrzyn G; Pierzynowska K Curr Issues Mol Biol; 2024 Mar; 46(3):2678-2700. PubMed ID: 38534785 [TBL] [Abstract][Full Text] [Related]
26. [Mucopolysaccharidoses--biochemical mechanisms of diseases and therapeutic possibilities]. Kloska A; Tylki-Szymańska A; Wegrzyn G Postepy Biochem; 2011; 57(2):133-47. PubMed ID: 21913414 [TBL] [Abstract][Full Text] [Related]
27. Quantitative estimation of lysosomal storage in mucopolysaccharidoses by electron microscopy analysis. Narajczyk M; Moskot M; Konieczna A Acta Biochim Pol; 2012; 59(4):693-6. PubMed ID: 23230565 [TBL] [Abstract][Full Text] [Related]
28. Osteoimmunology in mucopolysaccharidoses type I, II, VI and VII. Immunological regulation of the osteoarticular system in the course of metabolic inflammation. Opoka-Winiarska V; Jurecka A; Emeryk A; Tylki-Szymańska A Osteoarthritis Cartilage; 2013 Dec; 21(12):1813-23. PubMed ID: 23954699 [TBL] [Abstract][Full Text] [Related]
30. Changes in expression of signal transduction-related genes, and formation of aggregates of GPER1 and OXTR receptors in mucopolysaccharidosis cells. Pierzynowska K; Żabińska M; Gaffke L; Cyske Z; Węgrzyn G Eur J Cell Biol; 2022; 101(3):151232. PubMed ID: 35537249 [TBL] [Abstract][Full Text] [Related]
31. Protein aggregation and autophagy dysfunction: new lessons from mucopolysaccharidoses. Monaco A; Fraldi A Autophagy; 2021 Nov; 17(11):3875-3876. PubMed ID: 34407725 [TBL] [Abstract][Full Text] [Related]
32. Systems biology study of mucopolysaccharidosis using a human metabolic reconstruction network. Salazar DA; Rodríguez-López A; Herreño A; Barbosa H; Herrera J; Ardila A; Barreto GE; González J; Alméciga-Díaz CJ Mol Genet Metab; 2016 Feb; 117(2):129-39. PubMed ID: 26276570 [TBL] [Abstract][Full Text] [Related]
33. Community consensus for Heparan sulfate as a biomarker to support accelerated approval in Neuronopathic Mucopolysaccharidoses. Muenzer J; Ho C; Lau H; Dant M; Fuller M; Boulos N; Dickson P; Ellinwood NM; Jones SA; Zanelli E; O'Neill C Mol Genet Metab; 2024 Aug; 142(4):108535. PubMed ID: 39018614 [TBL] [Abstract][Full Text] [Related]
34. Decreased Levels of Chaperones in Mucopolysaccharidoses and Their Elevation as a Putative Auxiliary Therapeutic Approach. Żabińska M; Gaffke L; Bielańska P; Podlacha M; Rintz E; Cyske Z; Węgrzyn G; Pierzynowska K Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36840025 [TBL] [Abstract][Full Text] [Related]
35. Growth impairment in mucopolysaccharidoses. Melbouci M; Mason RW; Suzuki Y; Fukao T; Orii T; Tomatsu S Mol Genet Metab; 2018 May; 124(1):1-10. PubMed ID: 29627275 [TBL] [Abstract][Full Text] [Related]
36. Mucopolysaccharidoses Differential Diagnosis by Mass Spectrometry-Based Analysis of Urine Free Glycosaminoglycans-A Diagnostic Prediction Model. D'Avanzo F; Zanetti A; Dardis A; Scarpa M; Volpi N; Gatto F; Tomanin R Biomolecules; 2023 Mar; 13(3):. PubMed ID: 36979466 [TBL] [Abstract][Full Text] [Related]
37. Epilepsy in mucopolysaccharidosis disorders. Scarpa M; Lourenço CM; Amartino H Mol Genet Metab; 2017 Dec; 122S():55-61. PubMed ID: 29170080 [TBL] [Abstract][Full Text] [Related]
38. Substrate reduction therapies for mucopolysaccharidoses. Jakóbkiewicz-Banecka J; Piotrowska E; Gabig-Cimińska M; Borysiewicz E; Słomińska-Wojewódzka M; Narajczyk M; Węgrzyn A; Węgrzyn G Curr Pharm Biotechnol; 2011 Nov; 12(11):1860-5. PubMed ID: 21902626 [TBL] [Abstract][Full Text] [Related]
39. Proteasome Composition and Activity Changes in Cultured Fibroblasts Derived From Mucopolysaccharidoses Patients and Their Modulation by Genistein. Pierzynowska K; Gaffke L; Jankowska E; Rintz E; Witkowska J; Wieczerzak E; Podlacha M; Węgrzyn G Front Cell Dev Biol; 2020; 8():540726. PubMed ID: 33195185 [TBL] [Abstract][Full Text] [Related]